XML 61 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaborative Agreements (Details)
 1 Months Ended 9 Months Ended 12 Months Ended
Jun. 10, 2022
USD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Sep. 25, 2017
USD ($)
Aug. 15, 2017
USD ($)
Aug. 15, 2017
USD ($)
Aug. 31, 2016
USD ($)
Aug. 31, 2016
TWD ($)
Jul. 27, 2016
USD ($)
Dec. 24, 2018
Sep. 30, 2018
USD ($)
Sep. 25, 2017
USD ($)
May 26, 2017
USD ($)
Aug. 31, 2016
USD ($)
Aug. 31, 2016
TWD ($)
Jul. 27, 2016
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2017
USD ($)
Feb. 23, 2023
shares
Jul. 01, 2022
Aug. 05, 2019
USD ($)
shares
Jun. 30, 2019
USD ($)
shares
Collaborative Agreements (Details) [Line Items]                                                
Milestone payments royalty percentage                                   12.00% 12.00%          
Collaborative agreements, description                                   In addition to the total of NT$50 million, approximately equivalent to $1.64 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit.            
Co-Dev agreement, description                   On December 24, 2018, the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene’s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549.               the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene’s Common Stock, at the price of NT$50 (approximately equivalent to $1.64 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549.            
Eligible to receive payments $ 3,000,000                                              
Milestone regulatory payment amount period 3 years                                              
Loan amount                                   $ 1,000,000            
Percentage of working capital convertible loan                                   5.00%            
Conversion of shares, description                                   The Company may convert the Note at any time into shares of Rgene’s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note.            
Shares issued (in Shares) | shares                                         5,291,667      
Rgene Corporation [Member]                                                
Collaborative Agreements (Details) [Line Items]                                                
Ownership percentage                                   28.85% 28.85%     12.80%    
BHK Co-Development Agreement [Member]                                                
Collaborative Agreements (Details) [Line Items]                                                
Milestone payment               $ 31,649,000 $ 10,000,000           $ 31,649,000 $ 10,000,000                
Description of payment settlement                               ●Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment   ● Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment   ● At the completion of first phase II clinical trial: $1 million, or 10% of total payment   ● At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment   ● Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment   ●Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment ●Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment ●At the completion of first phase II clinical trial: $1 million, or 10% of total payment ●At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment ●Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment            
Upfront cash payment                                 $ 1,000,000              
Percentage of payments under co-development agreement                                 10.00%              
Total cash amount             $ 1,000,000             $ 1,000,000     $ 10,000,000              
Collaborative agreements, description                                 In 2015, the Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK. In 2015, the Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.64 million, as collaboration revenue when all research, technical, and development data was delivered to BHK. In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit.          
Co-Dev Agreement [Member]                                                
Collaborative Agreements (Details) [Line Items]                                                
Percentage of payments under co-development agreement                         50.00%         50.00%            
Compensation amount         $ 3,000,000 $ 3,000,000                                    
Addition cash payment                         $ 3,000,000         $ 3,000,000            
Additional paid-in capital     $ 3,000,000                                 $ 3,000,000        
Amount received     450,000                                 450,000        
Co-Dev Agreement [Member] | Rgene Corporation [Member]                                                
Collaborative Agreements (Details) [Line Items]                                                
Ownership percentage                                   6.40%            
Collaborative Agreement [Member]                                                
Collaborative Agreements (Details) [Line Items]                                                
Percentage of payments under co-development agreement                                   50.00% 50.00%          
Total cash amount   $ 3,000,000                 $ 3,000,000                          
Compensation amount                                   $ 3,000,000 $ 3,000,000          
Licensing rights       $ 3,000,000               $ 3,000,000                        
Research and development expense     3,000,000                                 3,000,000        
BioFirst Stock Purchase Agreement [Member]                                                
Collaborative Agreements (Details) [Line Items]                                                
Amount received                                             $ 2,902,911 $ 3,000,000
Shares issued (in Shares) | shares                                             414,702 428,571
Service Agreements [Member] | Rgene Corporation [Member]                                                
Collaborative Agreements (Details) [Line Items]                                                
Ownership percentage                                   31.62%            
Related Party [Member] | Co-Dev Agreement [Member]                                                
Collaborative Agreements (Details) [Line Items]                                                
Amount received     $ 450,000                                 $ 450,000